Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.
Actively Recruiting
Healthy Volunteer
Researchers are conducting an observational study to evaluate and optimize a blood test that detects colorectal cancer CRC by analyzing circulating free DNA cfDNA markers. This test focuses on detecting advanced precancerous lesions and early CRC in the United States population. The study aims to improve the performance of this blood-based assay for early CRC detection by collecting blood samples and clinical data from different participant groups. Participants include newly diagnosed CRC patients scheduled for surgery but not yet treated, patients confirmed with CRC by colonoscopy but not scheduled for surgery, and individuals at average risk undergoing routine colonoscopy screening. Blood samples and clinical information will be collected prospectively from these groups to support assay development and machine learning model training. During the study, participants will provide blood samples and clinical data before any cancer treatment. Researchers will analyze these samples to develop and validate the blood test. The study includes baseline assessment for assay development and ongoing machine learning training extending up to 24 months after the last participants involvement. Participants may be monitored for clinical data and sample collection over this period to support assay evaluation and optimization.
Actively Recruiting
This research aims to evaluate the safety and performance of the Enhanced Lithotripsy System ELS for treating urinary stones in adults. The study focuses on patients aged 21 or older who have a single urinary stone in the ureter. The purpose is to assess how well the ELS can break stones into small fragments that can pass more easily, potentially reducing discomfort. Participants will receive the ELS procedure, which uses low pressure ultrasound combined with microbubbles to pit and fragment the urinary stones. All participants undergo this experimental procedure, and no placebo or comparison group is involved. The study includes follow-up evaluations at 30 days and, if necessary, at 60 days to check for remaining stone fragments via CT scans. During the study, participants will be monitored for stone presence using CT imaging and assessed for changes in pain levels, quality of life, and return to normal daily activities and work. Safety and effectiveness will be evaluated up to 30 days after treatment, with an additional assessment at 60 days if stones remain. The total study duration extends from the procedure through these follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the CapsoCam4 Colon CV-3 endoscope system in detecting colonic polyps. This study aims to determine whether the AI-based computer-aided detection CADe feature improves the accuracy and efficiency of reading capsule videos. Colonoscopy results will be used as the reference standard to compare findings from the capsule system. Participants will prepare for and swallow the study capsule, which includes a new second-generation design. After the capsule procedure, participants will undergo a colonoscopy either the following day or between 3 to 6 weeks later. This allows researchers to compare the capsule findings with the colonoscopy results. During the study, participants will be monitored from the time of the capsule swallow up to the colonoscopy within 6 weeks. The main outcomes measured include the positive and negative percentage agreement between the capsule system and the colonoscopy in detecting polyps. Participants will complete required preparation and procedures, and safety and effectiveness data will be collected throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the Shield blood tests performance for colorectal cancer CRC screening in people aged 45 to 81 who are at average risk for CRC. The study focuses on assessing the test during a second round of screening, using colonoscopy as the reference standard. CRC is a common and serious disease, especially affecting older adults and certain minority groups, with early detection being key to improving outcomes. Participants will undergo the Shield blood test as part of their routine standard care, and their results will be compared to colonoscopy findings. This study is observational and collects real-world evidence over a period of 33 to 42 months after enrollment to assess how well the Shield test performs in detecting CRC or its precursors during the second screening interval. Participants will be involved in scheduled study procedures and standard care assessments, with data collected on the tests accuracy and effectiveness over time. The main outcome measured is the performance of the Shield test during the second testing period. The study will continue until December 2030, monitoring participants to gather long-term information about CRC screening efficacy in an average-risk population.
Actively Recruiting
Researchers are evaluating ORIC-944, a selective small molecule inhibitor targeting PRC2, in patients with metastatic prostate cancer. This open-label, phase 11b study aims to establish the safety and preliminary antitumor activity of ORIC-944 both alone and combined with androgen receptor pathway inhibitors ARPIs. The study involves patients who have progressed after prior ARPI therapies and explores dose escalation and optimization across different patient groups. Participants receive ORIC-944 orally once daily in 28-day continuous cycles either alone or combined with ARPIs such as abiraterone, apalutamide, darolutamide, or enzalutamide. The study has three parts Part I tests ORIC-944 alone Part II tests combinations with ARPIs Part III optimizes dosing of ORIC-944 with ARPIs in separate cohorts. Future combinations with abiraterone or enzalutamide may also be explored. During the study, participants undergo assessments including skin and tumor biopsies and monitoring of organ function and performance status. Researchers measure drug concentrations in the blood, antitumor responses, progression-free survival, and PSA levels. Safety and activity are evaluated over months, with follow-up for up to 36 months. The trial is sponsored by ORIC Pharmaceuticals and runs from 2022 to 2028.